PL1682091T3 - Kompozycje lipidów i kationowych peptydów - Google Patents

Kompozycje lipidów i kationowych peptydów

Info

Publication number
PL1682091T3
PL1682091T3 PL04798419T PL04798419T PL1682091T3 PL 1682091 T3 PL1682091 T3 PL 1682091T3 PL 04798419 T PL04798419 T PL 04798419T PL 04798419 T PL04798419 T PL 04798419T PL 1682091 T3 PL1682091 T3 PL 1682091T3
Authority
PL
Poland
Prior art keywords
lipids
compositions
cationic peptides
peptides
cationic
Prior art date
Application number
PL04798419T
Other languages
English (en)
Inventor
Fredrik Joabsson
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0326075A external-priority patent/GB0326075D0/en
Priority claimed from GB0326074A external-priority patent/GB0326074D0/en
Priority claimed from GB0412544A external-priority patent/GB0412544D0/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PL1682091T3 publication Critical patent/PL1682091T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL04798419T 2003-11-07 2004-11-05 Kompozycje lipidów i kationowych peptydów PL1682091T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0326075A GB0326075D0 (en) 2003-11-07 2003-11-07 Compositions
GB0326074A GB0326074D0 (en) 2003-11-07 2003-11-07 Method
GB0412544A GB0412544D0 (en) 2004-06-04 2004-06-04 Compositions

Publications (1)

Publication Number Publication Date
PL1682091T3 true PL1682091T3 (pl) 2017-09-29

Family

ID=34595630

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04798419T PL1682091T3 (pl) 2003-11-07 2004-11-05 Kompozycje lipidów i kationowych peptydów

Country Status (7)

Country Link
US (1) US8865021B2 (pl)
EP (1) EP1682091B1 (pl)
JP (1) JP5600233B2 (pl)
DK (1) DK1682091T3 (pl)
ES (1) ES2623881T3 (pl)
PL (1) PL1682091T3 (pl)
WO (1) WO2005046642A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
PL1848403T3 (pl) * 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
US9757461B2 (en) 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
EP1843746B1 (en) 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
KR101245022B1 (ko) 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
EP1888031B1 (en) * 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
US8097239B2 (en) 2005-06-06 2012-01-17 Camurus Ab Controlled-release formulations
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2044934A1 (en) * 2007-10-01 2009-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof
EP2052716B1 (en) * 2007-10-24 2014-12-31 Camurus AB Controlled release formulations
ATE513027T1 (de) * 2008-04-02 2011-07-15 Nestec Sa Funktionelle mesophasen auf oleylethanolamidbasis
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
EP2498754B1 (en) * 2009-06-25 2018-06-06 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Reverse hexagonal mesophases (h ii) and uses thereof
CN103702662B (zh) * 2011-05-25 2018-07-20 卡穆鲁斯公司 控制释放肽制剂
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
MX350929B (es) * 2011-12-05 2017-09-26 Camurus Ab Formulaciones peptidicas robustas de liberación controlada.
BR112014029425A2 (pt) 2012-05-25 2017-06-27 Camurus Ab pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito
HRP20210068T1 (hr) 2012-07-26 2021-03-05 Camurus Ab Opioidne formulacije
WO2014016428A1 (en) 2012-07-26 2014-01-30 Camurus Ab Opioid formulations
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586790B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
WO2017100580A1 (en) * 2015-12-10 2017-06-15 Aaron Seitz Sphingolipid coatings and process for manufacturing sphingolipid coatings effective for inhibiting biofilm formation
KR102186704B1 (ko) * 2019-02-18 2020-12-04 (주)아이엠디팜 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물
KR102628523B1 (ko) * 2020-06-30 2024-01-24 주식회사 종근당 GnRH 유도체를 포함하는 주사용 조성물
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
GR1010363B (el) * 2021-08-23 2022-12-21 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Νανοσωματιδια λυοτροπικων λιπιδικων υγρων κρυσταλλων για χρηση ως συστηματα μεταφορας δραστικων φαρμακευτικων ουσιων
RS66968B1 (sr) * 2021-08-23 2025-07-31 Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A Liotropni tečnokristalni nanosistemi sa inkapsuliranim bioaktivnim makromolekulima
GR1010458B (el) * 2022-07-21 2023-05-15 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Νανοσυστηματα βιοδραστικων μακρομοριων με πεπτιδικους δεσμους σε μορφη νανοδομημενων λυοτροπικων υγρων κρυσταλλων
GR1010501B (el) * 2022-06-08 2023-07-07 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Νανοσυστηματα βιοδραστικων μακρομοριων σε μορφη νανοδομημενων λυοτροπικων υγρων κρυσταλλων

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206593A (pt) 1991-10-04 1995-11-28 Gs Biochem Ab Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
JP2003520049A (ja) * 2000-01-18 2003-07-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトタンパク質であるチロシンホスファターゼのポリヌクレオチド、ポリペプチド、および抗体
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition

Also Published As

Publication number Publication date
EP1682091B1 (en) 2017-03-29
ES2623881T3 (es) 2017-07-12
WO2005046642A1 (en) 2005-05-26
US20070080323A1 (en) 2007-04-12
JP5600233B2 (ja) 2014-10-01
DK1682091T3 (en) 2017-05-15
JP2007510705A (ja) 2007-04-26
US8865021B2 (en) 2014-10-21
EP1682091A1 (en) 2006-07-26

Similar Documents

Publication Publication Date Title
PL1682091T3 (pl) Kompozycje lipidów i kationowych peptydów
PL377614A1 (pl) Kompozycje zawierające kwasy tłuszczowe i aminokwasy
EP1606315A4 (en) COMPOSITIONS AND THEIR USES COMPATIBLE TO ANY PRESENTING COMPLEX BINDING
PL2204168T3 (pl) Preparaty tetracyklin do jedorazowego dziennego podawania
EP1632213A4 (en) COSMETIC PREPARATION
IL197889A (en) Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same
IL176384A (en) Pyrrolidinochlorinated basazole and pharmacy preparations containing them
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
GB0214805D0 (en) Cosmetic compositions
GB0310791D0 (en) Improved cosmetic composition
EP1620089A4 (en) Therapeutic and prophylactic compositions and their uses
AU2003249114A8 (en) Cosmetic composition
AU2003293621A8 (en) Liposome-forming compositions
ZA200410163B (en) Improved distribution and preparation of germicidal compositions
TWI350750B (en) Compositions comprising cyclohexylamines and aminoadamantanes
GB2384705B (en) Cosmetic and related compositions
GB0324457D0 (en) Modified peptides and their uses
PL378052A1 (pl) Kationowe peptydy przeciwdrobnoustrojowe i sposoby ich zastosowania
GB0125449D0 (en) Cosmetic compositions
GB0310259D0 (en) Cosmetic compositions
SI1482967T1 (sl) Farmacevtski in kozmetični sestavki, ki vsebujejo PLGF-1
AU2003228896A8 (en) Anti-microbial peptides and compositions
EP1608970A4 (en) CCN3 COMPOSITIONS AND METHODS
AU2003901205A0 (en) Therapeutic and prophylactic compositions and uses therefor
GB0327050D0 (en) Therapeutic methods compositions and uses